Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
The $4M ‘Breakthrough’ award funds collaborative research aimed at destroying dormant disseminated tumor cells.
90% to 100% of study participants achieved complete or partial responses to treatment.
Researchers are learning how best to use this powerful modality while avoiding serious toxicities.
Engineered immune cells get a helping hand in a new clinical trial for multiple myeloma patients.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
The program will pay 65% of the cost of providing the custom-made immunotherapy.
“We have reason to hope that the basic principle could help glioblastoma patients. The next step is to work on a clinical trial to test it.”
Advocates are demanding that the Trump administration remove its restrictions and expand coverage for the cancer treatment.
Overall, the therapy worked very well in the mice used in the study. The first human clinical trial will be in adult brain cancers.
The researchers are now designing a first-in-human clinical trial to test the effectiveness of this approach in patients.
A look back at some of the major news stories we covered this year.
Long-term remission seen in children with leukemia and adults with lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.